BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome

Discovery of imatinib mesylate (IM) as the targeted BCR-ABL protein tyrosine kinase inhibitor (TKI) has resulted in its use as the frontline therapy for chronic myeloid leukemia (CML) across the world. Although high response rates are observed in CML patients who receive IM treatment, a significant...

Full description

Bibliographic Details

Main Authors:	Marjanu Hikmah Elias, Abdul Aziz Baba, Husin Azlan, Hassan Rosline, Goh Ai Sim, Menon Padmini, S. Abdul Wahid Fadilah, Ravindran Ankathil
Format:	Article
Language:	en
Published:	Elsevier 2024
Subjects:	BCR-ABL dependent mechanisms; Chronic myeloid leukemia; Imatinib mesylate; Mutation; Tyrosine kinase domain
Tags:	Add Tag No Tags, Be the first to tag this record!